Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (229)	11/25/2006 8:45:14 PM
From: technetium	Read Replies (1) \| Respond to of 360

Translation: "Our Drug Repositioning Division..." Novel idea. "We have invested, and continue to invest, significant amounts in the development of the Drug Repositioning technologies and of the Drug Repositioning Division." Sounds expensive. "...we do not typically derive up-front revenue. Generally, a partner agrees to make available a stated number of failed, stalled or deprioritized drug candidates as to which we will, at our expense, conduct the initial evaluation using our integrated multi-technology platform." Sounds expensive. "We will inform our partner of any possible new indications we identify. In some instances, our partner has the option to elect to have us conduct mutually agreed upon animal model validation studies based on our hypothesis, which may be partially or entirely at our expense." The partner might pay for mice if we prove it might work. Am I missing something?